These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 7262161)
81. [Cis-platinum in the treatment of disseminated testicular neoplasms resistant to classical chemotherapy]. Kuss R; Khoury S; Richard F; Fourcade R; Frantz P; Capelle JP J Urol Nephrol (Paris); 1978; 84(10-11):741-7. PubMed ID: 745255 [TBL] [Abstract][Full Text] [Related]
82. VP-16-213. A phase II trial using a weekly schedule. Karp G; Antman K; Canellos G Cancer Clin Trials; 1981; 4(4):465-7. PubMed ID: 7318129 [TBL] [Abstract][Full Text] [Related]
83. Phase II trial of etoposide, vincristine, and high-dose cisplatin in advanced non-small cell lung cancer. Bertrand M; Multhauf P; Presant C; Rappaport D; Blayney DW; Carr BI; Cecchi G; Doroshow JH; Emont E; Goldberg D Cancer Treat Rep; 1985 Nov; 69(11):1335-6. PubMed ID: 4092199 [No Abstract] [Full Text] [Related]
85. Phase II study of VP-16-213 versus dianhydrogalactitol in patients with metastatic malignant melanoma. Ahmann DL; Bisel HF; Edmonson JH; Hahn RG; O'Connell MJ; Frytak S Cancer Treat Rep; 1976 Nov; 60(11):1681-2. PubMed ID: 1021239 [No Abstract] [Full Text] [Related]
86. [Experiences with VP-16 in combination with cyclophosphamide or adriamycin in the anaplastic, predominantly small cell bronchogenic carcinoma]. Schmieder HA; Jungi WF; Mayr AC; Senn HJ Schweiz Med Wochenschr; 1979 Jun; 109(22):841-4. PubMed ID: 462156 [TBL] [Abstract][Full Text] [Related]
87. [Phase II study of etoposide in patients with lung cancer, with special reference to small cell carcinoma]. Kurita Y; Yokoyama A; Kinameri K; Matsuura N; Sano K Nihon Gan Chiryo Gakkai Shi; 1986 Feb; 21(1):108-11. PubMed ID: 3009665 [No Abstract] [Full Text] [Related]
88. Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC). Chapman R; Itri L; Gralla R; Kelsen D; Casper E; Golbey R Cancer Chemother Pharmacol; 1982; 7(2-3):205-7. PubMed ID: 7083460 [TBL] [Abstract][Full Text] [Related]
89. [Phase I clinical study of NK 171 (etoposide)]. Kimura K; Yamada K; Niitani H Gan To Kagaku Ryoho; 1985 Apr; 12(4):851-6. PubMed ID: 2985006 [TBL] [Abstract][Full Text] [Related]
91. [VP 16-213 in combination with endoxan, methotrexate and oncovin as polychemotherapy for bronchogenic carcinoma]. Ryssel HJ; Hasler E; Sonntag RW; Cavalli F; Martin J; Tschopp L; Brunner KW Schweiz Med Wochenschr; 1977 Jul; 107(26):912-5. PubMed ID: 877537 [TBL] [Abstract][Full Text] [Related]
92. Doxorubicin plus VP-16-213 for the treatment of refractory breast carcinoma. Konits PH; Van Echo DA; Aisner J; Morris D; Wiernik PH Am J Clin Oncol; 1982 Oct; 5(5):515-9. PubMed ID: 6758569 [TBL] [Abstract][Full Text] [Related]
94. [Results of the treatment of lymphatic neoplasms with Vepeside]. Pawlicki M; Sliz E Nowotwory; 1985; 35(2):145-50. PubMed ID: 3911173 [No Abstract] [Full Text] [Related]
95. Clinical trial of the oral form of a new podophyllotoxin derivative, VP-16-213 (NSC-141540), in patients with advanced neoplastic disease. Nissen NI; Hansen HH; Pedersen H; Stroyer I; Dombernowsky P; Hessellund M Cancer Chemother Rep; 1975; 59(5):1027-9. PubMed ID: 1106845 [No Abstract] [Full Text] [Related]
96. Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer. Ahmann DL; Bisel HF; Eagan RT; Edmonson JH; Hahn RG; O'Connell MJ; Frytak S Cancer Treat Rep; 1976 May; 60(5):633-5. PubMed ID: 1036468 [No Abstract] [Full Text] [Related]
97. [Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)]. Schmoll HJ; Niederle N; Achterrath W Klin Wochenschr; 1981 Nov; 59(21):1177-88. PubMed ID: 7031350 [TBL] [Abstract][Full Text] [Related]
98. [Use of vepeside in mono- and polychemotherapy of various malignant neoplasms]. Pawlicki M Nowotwory; 1983; 33(4):361-6. PubMed ID: 6369257 [No Abstract] [Full Text] [Related]
99. Review of etoposide single-agent activity. Schmoll H Cancer Treat Rev; 1982 Jun; 9 Suppl():21-30. PubMed ID: 6751532 [No Abstract] [Full Text] [Related]